Aprea Therapeutics Inc (APRE)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Christian S. Schade
Employees:
535 BOYLSTON STREET, BOSTON, MA 02116
6095104718

Clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. p53 is the protein expressed from the TP53 gene, the most commonly mutated gene in cancer. We believe that mutant p53 is an attractive therapeutic target due to the high incidence of p53 mutations across a range of cancer types and its involvement in key cellular activities such as apoptosis. Cancer patients with mutant p53 face a significantly inferior prognosis even when treated with the current standard of care, and a large unmet need for these patients remains. Our lead product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes, or MDS, and acute myeloid leukemia, or AML. APR-246 has received Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the EMA for MDS, AML and ovarian cancer, and we believe APR-246 will be a first-in-class therapy if approved by applicable regulators. We have commenced a pivotal Phase 3 trial of APR-246 with azacitidine for frontline treatment of TP53 mutant MDS and expect initial data from this trial in the second half of 2020. Our pivotal Phase 3 trial is supported by data from two ongoing Phase 1b/2 investigator initiated trials, one in the U.S. and one in France, testing APR-246 with azacitidine as frontline treatment in TP53 mutant MDS and AML patients.

Data derived from most recent annual or quarterly report
Market Cap 100.637 Million Shares Outstanding21.187 Million Avg 30-day Volume 1.749 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 30.99 / 3.17 Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million

Are you looking for this stock instead?

View SEC Filings from APRE instead.

View recent insider trading info

Funds Holding APRE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding APRE BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

151.4 Thousand total shares from 6 transactions

Exercise Derivative Conversion (M)

130 Thousand total shares from 4 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KORBEL GREGORY ALAN SVP, CHIEF BUSINESS OFFICER

  • Officer
42,412 2021-10-01 6

ABRAHMSEN LARS B. SVP, CHIEF SCIENTIFIC OFFICER

  • Officer
49,587 2021-10-01 3

ATTAR EYAL C. SVP, CHIEF MEDICAL OFFICER

  • Officer
83,331 2021-09-16 3

COIANTE SCOTT M SVP, CHIEF FINANCIAL OFFICER

  • Officer
91,466 2021-08-25 2

HENNEMAN JOHN B III

  • Director
32,360 2021-06-30 1

PETERS RICHARD

  • Director
27,360 2021-06-30 1

KELLY MICHAEL AARON

  • Director
27,360 2021-06-30 1

SEIZINGER BERND R.

  • Director
291,330 2021-06-30 1

NAMOUNI FOUAD

  • Director
27,360 2021-06-30 1

SCHADE CHRISTIAN S CHAIRMAN & CEO

516,660 2021-02-25 1

WESSELS GREGORY S. SVP, CHIEF COMMERCIAL OFFICER

82,000 2021-02-25 1

REDMILE GROUP, LLC

GREEN JEREMY

  • 10% Owner
No longer subject to file 2020-12-28 1

5AM VENTURES IV, L.P.

5AM CO-INVESTORS IV, L.P.

5AM PARTNERS IV, LLC

5AM OPPORTUNITIES I, L.P.

5AM OPPORTUNITIES I (GP), LLC

DIEKMAN JOHN D

SCHWAB ANDREW J.

PARMAR KUSH

ROCKLAGE SCOTT M

  • FORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDER
No longer subject to file 2020-10-05 0

KDEV INVESTMENTS AB

KAROLINSKA DEVELOPMENT AB

KCIF CO-INVESTMENT FUND KB

  • 10% Owner
No longer subject to file 2020-07-07 0

ROCKLAGE SCOTT M

0 2020-06-30 0

CHRISTENSON JOHAN

0 2020-06-30 0

HEPPLE JONATHAN

0 2020-06-30 0

5AM VENTURES IV, L.P.

5AM CO-INVESTORS IV, L.P.

5AM PARTNERS IV, LLC

DIEKMAN JOHN D

SCHWAB ANDREW J.

5AM OPPORTUNITIES I, L.P.

5AM OPPORTUNITIES I (GP), LLC

PARMAR KUSH

  • 10% Owner
2,212,654 2020-06-16 0

VERSANT VANTAGE I, L.P.

VERSANT VANTAGE I GP, L.P.

VERSANT VANTAGE I GP-GP, LLC

  • 10% Owner
No longer subject to file 2020-05-18 0

VERSANT V LUXCO S.A R.L.

VERSANT VENTURE CAPITAL V, L.P.

VERSANT AFFILIATES FUND V, L.P.

VERSANT OPHTHALMIC AFFILIATES I, L.P.

VERSANT VENTURE CAPITAL V (CANADA), LP

VERSANT VENTURES V, LLC

VERSANT VENTURES V (CANADA), L.P.

  • 10% Owner
No longer subject to file 2020-04-09 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

KORBEL GREGORY ALAN - Officer SVP, CHIEF BUSINESS OFFICER

2021-10-05 17:01:11 -0400 2021-10-01 M 27,500 d 25,245 direct

ABRAHMSEN LARS B. - Officer SVP, CHIEF SCIENTIFIC OFFICER

2021-10-05 17:01:43 -0400 2021-10-01 M 50,000 d 30,587 direct

KORBEL GREGORY ALAN - Officer SVP, CHIEF BUSINESS OFFICER

2021-10-05 17:01:11 -0400 2021-10-01 S 27,500 $4.89 d 17,167 direct yes 2.994 11.3772 11.3772 6 0.0 1

ABRAHMSEN LARS B. - Officer SVP, CHIEF SCIENTIFIC OFFICER

2021-10-05 17:01:43 -0400 2021-10-01 S 50,000 $4.89 d 19,000 direct yes 2.994 11.3772 11.3772 6 0.0 1

KORBEL GREGORY ALAN - Officer SVP, CHIEF BUSINESS OFFICER

2021-10-05 17:01:11 -0400 2021-10-01 M 27,500 $0.92 a 44,667 direct 2.994 11.3772 11.3772 6 0.0 1

ABRAHMSEN LARS B. - Officer SVP, CHIEF SCIENTIFIC OFFICER

2021-10-05 17:01:43 -0400 2021-10-01 M 50,000 $0.92 a 69,000 direct 2.994 11.3772 11.3772 6 0.0 1

ABRAHMSEN LARS B. - Officer SVP, CHIEF SCIENTIFIC OFFICER

2021-09-22 17:00:53 -0400 2021-09-20 M 25,000 d 80,587 direct

KORBEL GREGORY ALAN - Officer SVP, CHIEF BUSINESS OFFICER

2021-09-22 17:01:32 -0400 2021-09-20 M 27,500 d 52,745 direct

KORBEL GREGORY ALAN - Officer SVP, CHIEF BUSINESS OFFICER

2021-09-22 17:01:32 -0400 2021-09-20 S 5,460 $4.98 d 17,167 direct yes 0.2208 12.8035 13.6865 4 0.0 1

ABRAHMSEN LARS B. - Officer SVP, CHIEF SCIENTIFIC OFFICER

2021-09-22 17:00:53 -0400 2021-09-20 S 25,000 $4.97 d 19,000 direct yes 0.2208 12.8035 13.6865 4 0.0 1

KORBEL GREGORY ALAN - Officer SVP, CHIEF BUSINESS OFFICER

2021-09-22 17:01:32 -0400 2021-09-20 S 27,500 $4.97 d 17,167 direct yes 0.2208 12.8035 13.6865 4 0.0 1

ABRAHMSEN LARS B. - Officer SVP, CHIEF SCIENTIFIC OFFICER

2021-09-22 17:00:53 -0400 2021-09-20 M 25,000 $0.92 a 44,000 direct 0.2208 12.8035 13.6865 4 0.0 1

KORBEL GREGORY ALAN - Officer SVP, CHIEF BUSINESS OFFICER

2021-09-22 17:01:32 -0400 2021-09-20 M 27,500 $0.92 a 44,667 direct 0.2208 12.8035 13.6865 4 0.0 1

ATTAR EYAL C. - Officer SVP, CHIEF MEDICAL OFFICER

2021-09-20 17:29:34 -0400 2021-09-16 S 15,968 $4.68 d 83,000 direct yes -3.6403 10.2784 10.2784 6 -3.6403 2

KORBEL GREGORY ALAN - Officer CHIEF BUSINESS OFFICER

2021-09-14 17:01:08 -0400 2021-09-10 F 1,724 $4.59 d 22,627 direct 4.3103 -3.0172 9.0517 3 -3.0172 6

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
APREA THERAPEUTICS INC APRE 2021-10-22 22:15:03 UTC -1.5653 1.6353 600000
APREA THERAPEUTICS INC APRE 2021-10-22 21:45:03 UTC -1.5653 1.6353 600000
APREA THERAPEUTICS INC APRE 2021-10-22 21:15:03 UTC -1.5653 1.6353 600000
APREA THERAPEUTICS INC APRE 2021-10-22 20:45:03 UTC -1.48 1.55 600000
APREA THERAPEUTICS INC APRE 2021-10-22 20:15:03 UTC -1.48 1.55 600000
APREA THERAPEUTICS INC APRE 2021-10-22 19:45:03 UTC -1.48 1.55 650000
APREA THERAPEUTICS INC APRE 2021-10-22 19:15:03 UTC -1.48 1.55 650000
APREA THERAPEUTICS INC APRE 2021-10-22 18:45:03 UTC -1.5007 1.5707 650000
APREA THERAPEUTICS INC APRE 2021-10-22 18:15:03 UTC -1.5007 1.5707 650000
APREA THERAPEUTICS INC APRE 2021-10-22 17:45:03 UTC -1.5007 1.5707 650000
APREA THERAPEUTICS INC APRE 2021-10-22 17:15:03 UTC -1.5007 1.5707 650000
APREA THERAPEUTICS INC APRE 2021-10-22 16:45:03 UTC -1.5007 1.5707 650000
APREA THERAPEUTICS INC APRE 2021-10-22 16:15:04 UTC -1.5007 1.5707 650000
APREA THERAPEUTICS INC APRE 2021-10-22 15:45:03 UTC -1.5007 1.5707 650000
APREA THERAPEUTICS INC APRE 2021-10-22 15:15:03 UTC -1.5007 1.5707 650000
APREA THERAPEUTICS INC APRE 2021-10-22 14:45:03 UTC -1.4096 1.4796 650000
APREA THERAPEUTICS INC APRE 2021-10-22 14:15:03 UTC -1.4096 1.4796 650000
APREA THERAPEUTICS INC APRE 2021-10-22 13:45:03 UTC -1.4096 1.4796 650000
APREA THERAPEUTICS INC APRE 2021-10-22 13:15:03 UTC -1.4096 1.4796 650000
APREA THERAPEUTICS INC APRE 2021-10-22 12:45:03 UTC -1.4096 1.4796 650000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund APRE -2.0 shares, $-69.52 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund APRE -2.0 shares, $-69.52 2020-03-31 N-PORT

Elevate your investments